Kornimate/medical-research-clean huggingface dataset:
alternative to two-stage hepatectomy

Conditions: Colorectal Cancer; Liver Metastases

Summary: two-stage hepatectomy with or without portal vein embolization allows to treat multiple bilobar metastases expanding surgical indications for these patients. however, it has some related drawbacks: two operations are needed, and some patients do not complete the treatment strategy for disease progression. using experience gained from our ultrasound guided resection policy we explored the safety and effectiveness of one-stage surgical procedures in patients otherwise recommended for the two-stage approach.


Eligibility criteria:
inclusion criteria: 1. patients presenting with resectable colorectal cancer liver metastases (clm) 2. 4 or more lesions 3. bilobar involvement of the liver 4. contact or close adjacency (less than 0.5 cm) of at least one clm with major intrahepatic vascular structures (1st or 2nd order portal branches and/or hepatic vein at caval confluence). exclusion criteria: 1. patients with 3 or less resectable clm 2. patients with 4 or more resectable clm but nor bilobar 3. patients with 4 or more bilobar resectable clm without any lesion presenting condition of point 4 of the inclusion criteria

Keywords: intraoperative ultrasonography colorectal liver metastases hepatectomy portal vein embolization liver
evaluating a digital cognitive behavioral therapy for hazardous alcohol use: a pilot study in south korea

Conditions: High-risk Drinkers; Hazardous Alcohol Use

Summary: the goal of this single arm pilot study is to investigate the feasibility, acceptability and preliminary effectiveness of the mobile app sober; for reducing and preventing hazardous alcohol drinking. the main questions it aims to answer are: * feasibility: how well participants adhere to the app's lessons? * acceptability: participants\&#39; satisfaction with and perceived usefulness of the app. * preliminary effectiveness: the number of days participants remain abstinent. participants will: * use the mobile application sober, which delivers digital cognitive behavioral therapy, for four weeks. * wear a smartwatch to collect biometric data throughout the study. * visit the clinic three times: at baseline (v1), two weeks after the initial visit (v2), and four weeks after the initial visit (v3). * be evaluated using various questionnaires about their alcohol consumption, mood, and stress levels at each visit. * receive psychiatric consultation with a board-certified psychiatrist regarding their alcohol consumption, based on the data entered into the mobile app.


Eligibility criteria:
inclusion criteria: * individuals aged between 19 and 65 years. * individuals classified as high-risk drinkers (hazardous drinking): alcohol use disorder identification test (audit) score of 8 or higher * individuals who have been admitted for treatment of alcohol use disorder no more than once. * individuals who are assessed to have completed detoxification treatment for alcohol. * individuals who own a smartphone and can independently use apps on the smartphone. * individuals who voluntarily agree to participate in this clinical study and have signed the consent form (or whose representative has signed the consent form). exclusion criteria: * individuals with active and progressive physical illnesses or a life expectancy of less than 6 months * individuals with major psychiatric comorbidities such as schizophrenia, bipolar disorder, or major depressive disorder * pregnant women or those planning to become pregnant during the study * individuals who had participated in another clinical study within four weeks prior to the screening for this study

Keywords: digital intervention mobile app high-risk drinkers hazardous alcohol use secondary prevention digital cognitive behavioral therapy digital health
skin cancer oncology radiation evidence registry

Conditions: Non-melanoma Skin Cancer

Summary: to collect and analyze long term safety and efficacy outcomes of patients undergoing radiotherapy for non-melanoma skin cancer. a target of 400 vmat-treated sites is set which is estimated to be identified in approximately 350 participants. participants referred for radiotherapy for the management of non-melanoma skin cancer.

the registry will collect information on key clinical indications and patient reported outcomes to assess the safety and efficacy of vmat radiotherapy. data that will be collected includes baseline data of demographic, relevant medical history, photographs, treatment schedule, and treatment outcomes. data may be collected retrospectively in regard to previous relevant medical history, prior treatments and outcomes as well as prospectively, including treatment schedule and treatment outcomes of radiotherapy treatment. the registry aims to assess the safety and outcomes of treatment for up to 5 years. this registry will be the first of its kind in the us and will provide a basis for a number of potential research publications. the registry will also give insights into treatment delivery and potentially facilitate future improvements in patient care.

Eligibility criteria:
inclusion criteria: * over 18 years of age * diagnosed with a treatable non-melanoma skin cancer by referring medical practitioner * eligible to be treated using widefield (\>50cm2) vmat radiotherapy as determined by ro * patient has provided written informed consent. exclusion criteria: ♦ patients who do not consent to their involvement in the registry.
utilization of donor whole blood for blood transfusion in deceased donor liver transplantation

Conditions: Transfusion Related Complication; Liver Transplant

Summary: we will study 40 matched patients. 20 patients will receive leukoreduced whole blood from the solid organ donor. these 20 patients will be compared to 20 historical matched controls with regards to allogenic blood product usage and other physiologic markers


Eligibility criteria:
inclusion criteria: * - recipients 18 years or older. * deceased donor whole graft liver transplant recipients undergoing liver transplant starting 07/01/2020 and onwards at vumc. * abo-matched recipient and donor. * donor hb level \>/= 8 g/dl * recipients with negative abo antibody screen exclusion criteria: * - pediatric recipient. * hbs antigen+ donors * hcv nat+ donors * donors of a2 blood type * donors on oral anticoagulants (except for aspirin) over the past 3 days before organ procurement
hyperpolarized 13c-pyruvate metabolic mri with infiltrating gliomas

Conditions: Glioma

Summary: the purpose of this study is to examine the safety and feasibility of performing hyperpolarized metabolic mri in the diagnosis of brain tumor. this study will also assess the accuracy of hyperpolarized metabolic mri to diagnose intermediate to patients with infiltrating gliomas and examine the added utility of metabolic mri over standard mri imaging the fda is allowing the use of hyperpolarized \[1-13c\] pyruvate (hp 13c-pyruvate) in this study. up to 5 patients may take part in this study at the university of maryland, baltimore (umb).


Eligibility criteria:
inclusion criteria: * • patients with a new brain lesion interpreted as suspected infiltrating gliomas including but not limited to (diffuse astrocytoma who grade 2; oligodendroglioma who grade 2 and 3; anaplastic astrocytoma who grade 3; astrocytoma who grade 4), or, patients with prior history of infiltrating glioma scheduled for surgery for tumor biopsy or resection. * ages 18-80, including male and female * suitable to undergo contrast-enhanced mri * negative serum pregnancy test exclusion criteria: * inability to undergo mri scan * inability to receive iv contrast secondary to severe reaction or renal insufficiency.
treatment of acute pyelonephritis with gram negative strains in infants and children less than 3 years old

Conditions: Pyelonephritis

Summary: the purpose of this study is to demonstrate the equivalence of the therapeutic efficacy of cefixime by mouth (po) 10 days (d) and ceftriaxone intravenous route(iv) 4d followed by cefixime po 6d on renal scars 6 months after a first acute pyelonephritis episode. the investigators hypothesize that treatment with cefixime po will allow no more renal scars than intravenous route (iv) treatment of pyelonephritis in infants and children less than 3 years old, 6 months after the first episode. if it is true, treatment will no longer need hospitalisation and the advantages for children, families and the health system will be very important.

guidelines for treatment of acute pyelonephritis in infants and children are different from one country to another. the main question is the incidence of renal scars. intravenous route (iv) treatment is supposed to give the best results, but no previous study has ever given the incidence of renal scars after po treatment. this multicenter, randomised trial is an equivalence study of po and intravenous route (iv) treatments.

Eligibility criteria:
inclusion criteria: * infants and children more than 1 month old and less than 3 years old * first episode of acute pyelonephritis with gram negative strains * fever more than 38.5°c * procalcitonin (pct) value \> 0.5 ng/ml * urine obtained by transurethral bladder catheterization, suprapubic aspiration or midstream collection * urine exam: more than 100.000 leukocytes and gram negative strains + * normal hemodynamic exam * normal renal ultrasonography * positive dmsa renal scan for pyelonephritis during the first week after diagnosis * parental informed consent exclusion criteria: * newborn * children more than 3 years old * past urine infection * septic hemodynamic abnormalities * obstructive uropathy and any renal ultrasonography abnormalities * allergy to cefixime or ceftriaxone * antibiotic during the five previous days * gastrointestinal abnormalities able to interfere with antibiotic intake or absorption * absence of parental consent * social familial difficulties

Keywords: infant children pyelonephritis renal scars dmsa scan
central nervous system vascular changes in adult sickle cell disease and the effect of treatment with simvastatin

Conditions: Sickle Cell Disease; Stroke

Summary: stroke is a frequent complication of sickle cell disease (scd), with varying levels of central nervous system (cns) involvement. the summation of several ischemic events, even when silent, can lead to devastating consequences, from reduced academic performance to physical dependence. despite knowledge that brain flow velocities evaluated by doppler ultrasound identify pediatric scd patients at a greater stroke risk (adams et al, nejm 1998; 339:5-11), this method is not able to predict the occurrence of strokes in adults. there is also no consensus on the management of adult patients in relation to primary and secondary prevention. the aim of this study is to evaluate the effects of the administration of simvastatin on cns structural and functional vascular changes in 30 adult patients with scd (ss and sβ), above 35 years of age, observed through magnetic resonance imaging (mri). the data on the effect of simvastatin on disease manifestations is quite scarce, however this drug reportedly significantly reduces plasma concentrations of adhesion molecules and inflammatory markers, such as e-selectin, vegf, crp and il-6 (hoppe et al, bjh 2011; 153:655-663; hoppe et al, bjh 2017;177:620-629). thus, in addition to the search for early diagnostic markers and risk stratification for primary or recurrent stroke, we will also compare cns images before and 12 months after the administration of simvastatin. the drug alter stroke recurrence rates in the general adult population, but their effects on vascular changes in patients with scd have not yet been adequately elucidated. this is particularly important because these are low cost drugs which present good tolerability, and could be part of the therapeutic arsenal of scd, even in low income settings. concomitantly with the cns evaluation, this study also intends to investigate molecular pathways that may be affected by the drugs. we will evaluate microvesicle release patterns, as well as the content of micrornas possibly involved in the occurrence of stroke, in addition to metabolomic studies and plasma cytokine profile.


Eligibility criteria:
inclusion criteria: * diagnosis of sickle cell disease exclusion criteria: * previous stroke * some relevant concomitant clinical condition (cancer, aids, inflammatory / autoimmune diseases, etc.). * pregnancy * individuals considered to be vulnerable (minors,institutionalized individuals, patients with a history of psychiatric illness with cognitive impairment or incapacity)
comparison of clinical efficacy of a dentifrice containing 5% fluoro calcium phosphosilicate to a dentifrice containing calcium sodium phosphosilicate on dentinal hypersensitivity

Conditions: Dentinal Hypersensitivity

Summary: aim of this study was to assess and compare the efficacy of a dentifrice containing 5% fluoro calcium phosphosilicate and dentifrice containing calcium sodium phosphosilicate on dentinal hypersensitivity (dh) compared to a placebo over a period of 6 weeks.

a total of 131 subjects were divided into 3 groups randomly. group i was given the dentifrice containing 5% fluoro calcium phosphosilicate ,group ii was given the dentifrice containing calcium sodium phosphosilicate and group iii was given placebo. sensitivity scores (vas score) were recorded at baseline, 2 weeks, 6 weeks.

Eligibility criteria:
inclusion criteria: * the volunteers selected at baseline were in good general health and should have at least 20 natural permanent teeth and history of hypersensitivity to hot, cold, sour stimuli on at least two teeth with a vas score of ≥4. exclusion criteria: * patients with active cervical caries or deep abrasion requiring cervical filling, chipped teeth or fractured cusps, tender tooth in same quadrant as the hypersensitive teeth, subjects using any type of desensitizing paste or desensitizing therapy for last 6 months, pregnant/ lactating women or subjects with history of chronic use of anti-inflammatory and analgesic medications were excluded.

Keywords: dentinal hypersensitivity visual analog scale
minimal invasive imaging of coronary artery disease in patients with asymptomatic myocardial injury after major non-cardiac surgery.

Conditions: Myocardium; Injury; Coronary Artery Disease

Summary: this is a cross-sectional pilot study to assess coronary artery disease with minimal invasive techniques in patients with asymptomatic troponin elevation after noncardiac surgery. the primary objective is to quantify coronary artery disease, as determined by coronary ct and mr, as a cause of postoperative myocardial injury. the secondary objective is to correlate coronary calciumscore to postoperative levels of troponin.


Eligibility criteria:
inclusion criteria: * major noncardiac surgery with a planned minimal postoperative hospital stay of 2 days * age \> 59 years * troponin_i elevation \> 0.06 ng/ml in the first 3 post-operative days * no clinical symptoms of myocardial ischemia exclusion criteria: * perioperative troponin elevation due to other factors than coronary artery disease such as proven pulmonary embolism or sepsis * perioperative st-elevation myocardial infarction (stemi) * perioperative symptomatic angina with troponin elevation * patients with a history or ecg-signs of myocardial infarction * patients with pre-existent heart failure, left ventricular dysfunction, significant valvular disease or left ventricle hypertrophy * patients with significant valvular disease or left ventricle hypertrophy determined postoperatively with echocardiography. * contra-indication for cmr such as claustrophobia or metal prosthesis * allergic reaction to ct-contrast or gadolinium * renal dysfunction with gfr \< 50 ml/min, as determined after the operation * unstable hemodynamics or other conditions disabling transport to the radiology department * expected major discomfort or substantial increase in pain sensation by undergoing ccta or cmr * admission at the icu * poor prognosis due to other medical conditions e.g. malignancy
a study to evaluate dcr-phxc in children and adults with primary hyperoxaluria type 1 and primary hyperoxaluria type 2

Conditions: Primary Hyperoxaluria Type 1 (PH1); Primary Hyperoxaluria Type 2 (PH2); Kidney Diseases; Urologic Diseases; Genetic Disease

Summary: the purpose of this study is to evaluate the efficacy and safety of dcr-phxc in children and adults with primary hyperoxaluria type 1 (ph1) and primary hyperoxaluria type 2 (ph2)


Eligibility criteria:
key inclusion criteria: * capable and willing to provide written informed consent or assent * documented diagnosis of ph1 or ph2, confirmed by genotyping * must meet the 24 hour urine oxalate excretion requirements * less than 20% variation between the two 24-hour urinary creatinine excretion values derived from the two 24-hour urine collections in the screening period * estimated gfr at screening ≥ 30 ml/min normalized to 1.73 m2 bsa key exclusion criteria: * renal or hepatic transplantation (prior or planned within the study period) * currently on dialysis or anticipated requirement for dialysis during the study period * plasma oxalate \>30 µmol/l * documented evidence of clinical manifestations of systemic oxalosis (including pre-existing retinal, heart, or skin calcifications, or history of severe bone pain, pathological fractures, or bone deformations) * use of an rna interference (rnai) drug within the last 6 months * participation in any clinical study in which you received an investigational medicinal product (imp) within 4 months before screening * liver function test (lft) abnormalities: alanine aminotransferase (alt) and/or aspartate aminotransferase (ast) \>1.5 times upper limit of normal (uln) for age and gender * inability or unwillingness to comply with study procedures

Keywords: ph1 ph2 primary hyperoxaluria rnai rnai therapeutic galnac ldha gene ldh sirna
early feto for severe congenital diaphragmatic hernia

Conditions: Congenital Diaphragmatic Hernia

Summary: congenital diaphragmatic hernia (cdh) is associated high mortality and morbidity, mainly in those cases with severe forms where there are extremely reduced lung volumes, liver herniation and decreased abnormal pulmonary vascularization. fetal endoscopic tracheal occlusion performed between 26 and 30 weeks (standard feto) has been shown to increase fetal pulmonary size and vascularity, and to improve infant survival in isolated severe cdh. fetal pulmonary response followed feto can be used to predict outcome and is dependent on the size of the fetal lung prior to the procedure. we hypothesize that performing an earlier feto, between 22-24 weeks, fetuses with severe form of cdh will have a better fetal pulmonary response and higher chance of surviving.

we pretend to investigate if "early feto" will improve the survival rate and the fetal pulmonary response, by conducting a randomized controlled trial comparing the results with those fetuses that undergo to "standard feto" (between 26-28 weeks).

Eligibility criteria:
inclusion criteria: * fetuses with isolated congenital diaphragmatic hernia (normal fetal karyotype and absence of any associated structural anomaly); * gestational age established by last menstruation and/or first trimester ultrasonography; * prenatal diagnosis of congenital diaphragmatic hernia before 24 weeks of gestation * severe congenital diaphragmatic hernia (at 24 weeks, lung-to-head ratio \<1.0 and at least 1/3 of the liver herniated into the fetal thorax) * written informed consent (by the patient) exclusion criteria: * preterm premature rupture of the membranes before randomization * preterm labor before randomization

Keywords: congenital diaphragmatic hernia fetoscopy fetal endoscopic tracheal occlusion pulmonary hypoplasia fetal surgery fetal lung
a trial of sb-061 in osteoarthritis of the knee

Conditions: Osteoarthritis

Summary: this study evaluates a novel agent, sb-061, for the treatment of osteoarthritis of the knee. half of the patients will receive the agent via intra-articular injection and half will receive a placebo injection.

the treatment of pain associated with osteoarthritis may include periodic intra-articular injections of corticosteroids or viscosupplements such as hyaluronic acid. sb-061 is anticipated to relieve osteoarthritis pain by reinforcing the cartilage matrix and providing a lubricating coating of the cartilage. subjects will receive 2 intra-articular injections of either sb-061 or placebo and be followed for 3 months to evaluate pain amelioration. subjects and investigators are blinded to treatment allocation.

Eligibility criteria:
inclusion criteria: * femorotibial osteoarthritis of the knee * radiological oa kellgren-lawrence grade 2 or 3 * womac pain 1 score of the target knee of ≥4 and ≤ 9 exclusion criteria: * hypersensitivity to medications or to intra-articular injections * intra-articular delivery of corticosteroids or hyaluronic acid in the target knee within 6 months of study * high dose systemic corticosteroid treatment of longer (\>14 days) duration w/in 6 months of study * major surgery or arthroscopy of the target knee within year prior to study * planned surgery in the target knee within the next 3 months * concomitant inflammatory disease affecting either knee

Keywords: knee
effects of internet support for cancer patients

Conditions: Breast Cancer

Summary: being diagnosed and treated for cancer is usually associated with severe physical symptoms, impaired functional status, complex emotional, psychosocial and existential issues and substantial worries. failure to help patients with their problems and worries can unnecessarily delay patients' recovery and rehabilitation, lead to chronic functional impairments, anxiety and depression and prolong patients' needs for health care and social services. the objectives of this interdisciplinary, international research project that includes collaboration with helfo (the norwegian health economy administration), are to test and compare, in a randomized, controlled trial (rct), the effects of (1) a practice-integrated online patient-provider communication (oppc) service including access to asking questions to helfo, (2) a multi-component interactive health communication application (ihca) called webchoice, and (3) usual care on: patient outcomes, health care and social services use and costs. breast cancer patients undergoing treatment at three different hospitals in norway will be randomized into two experimental and one control groups and will be followed with 5 repeated measures over one year. the proposed study will contribute to innovative methods and technologies that can radically improve patient-provider communication, care quality, and continuity of care. the two interventions tested in this study, the oppc service with and without additional features of webchoice, represent new forms of interactions and information sharing between patients and clinicians where patients can get seamless access to communication and information services from where and whenever they need it. this could significantly contribute to reducing unnecessary suffering, less fragmented health care, better efficiency, patient safety, patient satisfaction and have an impact on patients' health services utilization. the investigators' work addresses, therefore, important health policy goals with the potential for considerable societal gains.


Eligibility criteria:
inclusion criteria: * patients recently diagnosed with breast cancer and under treatment (radiation, chemotherapy, hormone, or combinations of those) * patients are \> 18 years of age, able to write / read / speak norwegian and have internet with secure access (bankid) at home exclusion criteria: * excluded are patients who had received radiation on the brain as this may affect their abilities to reliably report their symptoms

Keywords: symptom management interactive health communication application patient-provider communication health care costs